Theragen Receives Patent for Spine Fusion Bone Growth Stimulator System

A U.S. Patent has been issued acknowledging Theragen’s innovative approach to the development of the ActaStim-S Spine Fusion Bone Growth Stimulator system.
 
The first new Spine Fusion Stimulator on the market in decades, ActaStim-S blends clinically proven therapeutic stimulation with modern design and a data-rich digital health platform. The system not only promotes healing, it encourages patient compliance, engagement, and informed dialogue with healthcare providers during the critical — and lengthy — post-operative fusion process.
 
“Spinal fusion is a healing process, often characterized as a race to achieve solid fusion before failure of the implanted hardware,” says co-inventor and Theragen CEO Chris McAuliffe. “Electrical stimulation is a clinically proven, safe and effective post-operative adjunct therapy that can help patients win that race, however its clinical effectiveness requires regular use over several months.”
 
“That’s why we’ve taken a user-centric approach, designing a more wearable device that also offers a digital health component that gives patients the unique opportunity to engage in, follow, and truly impact their own recovery.”
 
COO, VP of R&D, and co-inventor Richard Pearce explains further: “The system includes a remarkably discreet, unobtrusive wearable unit that is very well received by patients. It includes utilization tracking, on-board activity sensing, Bluetooth smartphone connectivity, and an intuitive app that helps patients visualize their progress over time.”
 
Pearce continued, “The essence of this new U.S. Patent (#11,394,919) is focused on ensuring that this connectivity does not interfere with ease of use — and that data collection and transfer can happen quickly and effectively.”